Class Ii was Meihua International Medical Technologies’s largest revenue line in fiscal 2025, bringing in $42.35M of $61.79M (69%).
| Government Category | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Class Ii | $73.41M | $72.70M | $68.45M | $42.35M |
| Class I | $16.04M | $14.96M | $20.92M | $10.82M |
| Other | $10.85M | — | — | — |
| Others | — | $6.97M | $5.81M | $5.28M |
| Class Iii | $3.05M | $2.47M | $1.72M | $1.72M |
| Saas Development Service | — | — | — | $1.62M |
| Total | $103.35M | $97.10M | $96.91M | $61.79M |
Meihua International Medical Technologies brought in $61.79M from its five revenue lines in fiscal 2025, the year ended December 31, 2025. Meihua International Medical Technologies regrouped these revenue lines after fiscal 2024, so the total does not compare directly with that year's $96.91M. Class Ii was the largest at $42.35M (68.5%), ahead of Class I at $10.82M (17.5%) and Others at $5.28M (8.5%). The other two revenue lines brought in $3.34M combined.
Compared with fiscal 2024, every revenue line above 2% of revenue shrank. Class Iii held up best, down 0.2% to $1.72M, and Class I fell the most, down 48.3% to $10.82M.
Meihua International Medical Technologies began breaking out Others in fiscal 2023 and Saas Development Service in fiscal 2025. Meihua International Medical Technologies stopped reporting Other as a separate revenue line after fiscal 2022, when it brought in $10.85M.
Purchased was Meihua International Medical Technologies’s largest product and service line in fiscal 2025, bringing in $34.51M of $61.79M (56%).
| Product and Service | FY 2021 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Class Ii | — | — | — | |
| Purchased | $48.90M | $49.30M | $34.51M | |
| Produced | $48.20M | $47.61M | $27.28M | |
| Class I | — | — | — | |
| Others | — | — | — | |
| Class Iii | — | — | — | |
| Total | $97.10M | $96.91M | $61.79M |
Meihua International Medical Technologies brought in $61.79M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 36.2% from $96.91M in fiscal 2024. Purchased was the largest at $34.51M (55.9%), ahead of Produced at $27.28M (44.1%).
Compared with fiscal 2024, Purchased fell 30.0% to $34.51M and Produced fell 42.7% to $27.28M. From fiscal 2023 to 2025, combined revenue from these lines fell from $97.10M to $61.79M, a compound annual decline of 20.2%. Purchased's share of the total rose from 50.4% to 55.9%.
Third Party Sales was Meihua International Medical Technologies’s largest revenue line in fiscal 2025, bringing in $60.96M of $61.79M (99%).
| Related and Nonrelated Parties | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Third Party Sales | $103.32M | $96.68M | $96.14M | $60.96M | |
| Related Party | $29.20K | $416.44K | $768.55K | $831.33K | |
| Yangzhou Meihua Import & Export Co., Ltd | $18.78K | — | — | — | |
| Shanghai Xinya Pharmaceutical Hanjiang Co., Ltd | $10.42K | — | — | — | |
| Total | $103.38M | $97.10M | $96.91M | $61.79M |
Meihua International Medical Technologies brought in $61.79M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. That was down 36.2% from $96.91M in fiscal 2024. Third Party Sales was the largest at $60.96M (98.7%), ahead of Related Party at $831.33K (1.3%).
Meihua International Medical Technologies stopped reporting Yangzhou Meihua Import & Export Co., Ltd ($18.78K in fiscal 2022) and Shanghai Xinya Pharmaceutical Hanjiang Co., Ltd ($10.42K in fiscal 2022) as separate revenue lines.
Meihua International Medical Technologies (MHUAF) reports its revenue by government category, by product and service and by related and nonrelated parties. In fiscal 2025, Class Ii was its largest revenue line, bringing in $42.35M (68.5% of the total), followed by Class I at $10.82M (17.5%).
Class Ii was Meihua International Medical Technologies' largest revenue line in fiscal 2025, bringing in $42.35M, or 68.5% of the $61.79M total across its five revenue lines.
Purchased was Meihua International Medical Technologies' largest product and service line in fiscal 2025, bringing in $34.51M, or 55.9% of the $61.79M total across its two product and service lines.
Every figure comes from Meihua International Medical Technologies' annual financial filings, as reported. Each line keeps the name Meihua International Medical Technologies gives it, and years follow its fiscal calendar.
Meihua International Medical Technologies' revenue by government category goes back to fiscal 2022, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.